Jennerex products are the first in a novel, revolutionary, breakthrough product class of cancer therapeutics - vaccinia viruses that have been engineered to target, attack and eradicate cancer without harming the surrounding cells.
Unlike "vectors" or "vaccines", Jennerex products replicate (multiply) themselves in cancer cells, leading to cancer cell destruction, while normal cells are left unharmed. Our products are activated ("turned on") by genetic pathways that are critical to the vast majority of human cancers, including common solid tumors such as lung, colon, prostate, breast, pancreas and melanoma. They employ a novel primary mechanism-of-action that is effective even against cancers that are resistant to standard therapies such as chemotherapy, small molecule tyrosine kinase inhibitors, antibodies and radiotherapy. Simultaneously, a therapeutic cascade is initiated by product replication resulting in tumor vasculature shutdown and anti-tumoral immune attack. In addition, we can "arm" our products with therapeutic payloads that destroy cancers by complementary and synergistic mechanisms. As a result, our first-in-class products wage a targeted and multi-pronged attack on cancer.